Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Status:
RECRUITING

Trial end date:
2031-05-21

Target enrollment:

Participant gender:

The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.

PHASE1

Amgen

MediLink

atezolizumab
durvalumab